Hamburg Gives Rallying Cry For FDA Power In Her Public Farewell
This article was originally published in The Tan Sheet
Executive Summary
The outgoing commissioner gives forceful defense of the agency’s regulatory authority and warns that lowering drug approval standards would damage patients and industry.
You may also be interested in...
Hamburg Departure Hinged On Filling FDA Leadership Roster
Susan Mayne brings “new strength and focus to CFSAN and medical countermeasures expert Luciana Borio moves to chief scientist role. Hamburg offers previews on leadership approaches of Stephen Ostroff and Robert Califf.
NASH Drug Development: Experts Argue The Case For Noninvasive Tests As Surrogate Endpoints For Approval
However, FDA officials appear skeptical that imaging-based and circulating biomarkers are ready for prime time when it comes to supporting accelerated approval of drugs for noncirrhotic nonalcoholic steatohepatitis.
Drug Promotion: Growth In Digital Marketing Warrants New Oversight Approaches, Experts Say
Panelists at a recent Duke-Margolis meeting cite growing use of native ads and patient influencers, as well as the limited attention given to presentation of risk information, in calling for a re-examination of how pharmaceutical promotion on digital platforms is regulated.